TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7695323
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil oral suspension with food
Study: 7695323
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil oral suspension under fasting conditions
Study: 2695815
Drug: 100 I.U.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 I.U. of salmon calcitonin (sCT) nasal spray daily (n = 20)
Study: 2695815
Drug: 100 I.U.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 I.U. of sCT by subcutaneous injection every second day (n = 10)
Study: 2695815
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplement, 1 g per day (control group, n = 10)
Study: 2695815
Drug: Calcitonin groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin groups (sCT nasal spray and subcutaneous injection)
Study: 334475
Drug: Flurbiprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (150 mg to 300 mg daily)
Study: 334475
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg to 150 mg daily)
Study: 3540229
Drug: Verapamil 160
Normalized name: verapamil 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 160 mg twice daily
Study: 3540229
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg twice daily
Study: 24188511
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Therapy (FFT‐CHR)
Study: 20556928
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily fixed combination latanoprost-timolol
Study: 20556928
Drug: Timolol 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.50% twice daily associated with once daily latanoprost
Study: 20556928
Drug: Timolol 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.50% twice daily (control group)
Study: 16950210
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (BUP) 16 mg/d
Study: 12074403
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 4-10 ng/ml
Study: 12074403
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels >10 ng/ml
Study: 10091816
Drug: Beta-adrenergic blocking
Normalized name: beta-Adrenergic Blocking Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blocking agents
Study: 10091816
Drug: Beta-adrenergic blocking
Normalized name: beta-Adrenergic Blocking Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blocking agents + Enalapril
Study: 10091816
Drug: Control (nonuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonuse of beta-blockers)
Study: 2108614
Drug: UFT 600
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 600 mg/body/day (Group C)
Study: 2108614
Drug: UFT 400
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 400 mg/body/day for 12 months (Group D)
Study: 2108614
Drug: UFT (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (dosage between 8 to less than 12 mg/kg)
Study: 2108614
Drug: UFT (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (dosage more than 12 mg/kg)
Study: 2108614
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of UFT
Study: 2108614
Drug: Discontinued administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinued administration of UFT
Study: 155295
Drug: Ipratropium (Atrovent)
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium (Atrovent) 0.125 mg x 4 daily
Study: 155295
Drug: Terbutalin (Bricanyl)
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutalin (Bricanyl) 5 mg x 4 daily
Study: 28337029
Drug: High-protein energy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein energy restriction (HP-ER, 1.7 g kg-1 per day)
Study: 28337029
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein energy restriction (NP-ER, 0.9 g kg-1 per day)
Study: 15248820
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (1.7 microg/kg per day)
Study: 9159303
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of hypertonic dialysate in small-volume CAPD (3 x 2 L daily exchange)
Study: 8254063
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (N = 15)
Study: 3425219
Drug: Intrarectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal administration of diazepam
Study: 3425219
Drug: Intrarectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal administration of midazolam
Study: 3425219
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of diazepam
Study: 25523430
Drug: 13.3 mg/24
Normalized name: Exelon, 13.3 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.3 mg/24 h rivastigmine patch with memantine
Study: 25523430
Drug: 13.3 mg/24
Normalized name: Exelon, 13.3 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.3 mg/24 h rivastigmine patch alone
Study: 25523430
Drug: 4.6 mg/24
Normalized name: Exelon, 4.6 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.6 mg/24 h rivastigmine patch with memantine
Study: 25523430
Drug: 4.6 mg/24
Normalized name: Exelon, 4.6 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.6 mg/24 h rivastigmine patch alone
Study: 10864554
Drug: Sulphonylureas or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylureas or Insulin
Study: 1373956
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with Kcal/g N2 = 100
Study: 1373956
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with Kcal/g N2 = 150
Study: 6487494
Drug: Trazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100 mg) + Ethanol (0.5 ml/kg)
Study: 6487494
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg) + Ethanol (0.5 ml/kg)
Study: 6487494
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 ml/kg)
Study: 28708705
Drug: Patient-guided (PG)
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-guided (PG) shock wave treatment
Study: 28708705
Drug: Ultrasound-guided (UG)
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided (UG) shock wave treatment
Study: 25465773
Drug: DSIG cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSIG cream
Study: 25465773
Drug: Topical mouth
Normalized name: HYDROGEN PEROXIDE 15 mg in 1 mL TOPICAL MOUTHWASH [Sore Mouth Cleanser]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mouth rinse
Study: 23494116
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) with methylprednisolone 1 ml
Study: 23494116
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (LAI) with procaine 1 ml 2%
Study: 23494116
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (LAI)
Study: 20663113
Drug: Postoperative quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative quality of life measured using Functional Status Index (FSI), Visual Analogue Score (VAS)‐Fatigue, and Functional Assessment of Cancer Therapy Anemia (FACT‐Anemia) subscale
Study: 19114224
Drug: Guggul (2160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guggul (2160mg daily for 12 weeks)
Study: 15010623
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg orally three times a day after 30 mg ketorolac intravenously every 6 hours until able to take oral medications)
Study: 11357169
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-1 receptor antagonist (IL-1ra)
Study: 30150152
Drug: Intraoperative periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular injection (PAI) with liposomal bupivacaine (LB)
Study: 23939263
Drug: 100,000 U
Normalized name: nystatin 100,000 UNT Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 U of oral cholecalciferol every 3 months for 1 year
Study: 12614286
Drug: Standard steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid therapy (n = 43)
Study: 12614286
Drug: Standard steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid therapy group
Study: 11030295
Drug: Acid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid infusion into the lower oesophagus
Study: 10165095
Drug: Telephone-assisted weight-loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-assisted weight-loss program (weekly calls)
Study: 24755313
Drug: Noncalcified nodules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncalcified nodules (NCNs) observed on low-dose computed tomography (LDCT)
Study: 23001003
Drug: Intermittent isometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent isometric fatigue task at 60% of daily peak force
Study: 23001003
Drug: Intermittent isometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent isometric fatigue task at 70% of daily peak force
Study: 21178138
Drug: VIR-576 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-576 (5.0 grams per day, intravenous infusion)
Study: 8695133
Drug: Supplemental O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental O2 administered by bag‐valve‐mask during transport, followed by 40% face shield in the PACU
Study: 8695133
Drug: Supplemental O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental O2 by nasal cannula at 4 L/min during transport and PACU stay
Study: 8257839
Drug: Suo Quan
Normalized name: Yan Hu Suo (Corydalis Ambigua)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suo Quan pill
Study: 8257839
Drug: Placebo (neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (neutral pill)
Study: 30614016
Drug: Treatment speed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment speed
Study: 30028929
Drug: Light-cured anesthetic
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-cured anesthetic gel
Study: 27598511
Drug: 5‐mg VILD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg VILD
Study: 23064240
Drug: edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 60 mg once daily × 7 days
Study: 23064240
Drug: digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin 0.25 mg twice daily × 2 days and once daily × 5 days
Study: 15759817
Drug: Thymosin alpha-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha-1 (T-alpha1) 1.6 mg subcutaneously twice weekly
Study: 15759817
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) 5 million IU daily for 15 days, then thrice weekly for 6 months
Study: 1718251
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment of recurrent neovascularization
Study: 1718251
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional laser treatment
Study: 29891331
Drug: Adiponectin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin concentration >4.22 µg/mL
Study: 27098538
Drug: Microbial cell
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial cell preparation
Study: 23020264
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol (10 mg every 5‐10 minutes to a maximum of 80 mg, slowly)
Study: 23020264
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.15 mg/kg to a maximum of 16 mg, slowly)
Study: 20863004
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg orally for 11 days
Study: 20863004
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg orally for 11 days
Study: 12401613
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 40 mg (Group L)
Study: 10201104
Drug: Positive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive and negative reinforcement with concurrent choice options including parent attention and preferred toys
Study: 6991164
Drug: Exogenous androstenedione
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous androstenedione administration
Study: 26457343
Drug: Fludrocortisone 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0.4 mg
Study: 21302161
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (100 ng/mL plasma)
Study: 16904123
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to novel words in meaningful text or in isolation; number of exposures manipulated (once, twice, or four times)
Study: 3394914
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (10 mg) with oral diazepam (0.2 mg/kg)
Study: 3394914
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam (0.2 mg/kg) alone
Study: 25790946
Drug: Rapid palatal
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid palatal expansion (RPE) therapy
Study: 21564138
Drug: Topical cosmetic
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol
Study: 18279921
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (5 metered doses of 10% lidocaine)
Study: 18279921
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (10 mL)
Study: 18279921
Drug: Plain lubricating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lubricating gel (10 mL)
Study: 26414004
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week for 12 weeks
Study: 24018240
Drug: ONO-8539 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-8539 (30 mg)
Study: 24018240
Drug: ONO-8539 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-8539 (100 mg)
Study: 24018240
Drug: ONO-8539 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-8539 (300 mg)
Study: 24018240
Drug: Tolterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (4 mg)
Study: 24018240
Drug: ONO-8539 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-8539 (30, 100, 300 mg)
Study: 18356686
Drug: Single Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Aspirin (100 mg)
Study: 18356686
Drug: Single Propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Propranolol (80 mg)
Study: 12402619
Drug: rHuEPO (40-70
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (40-70 subcutaneous units/kg weekly)
Study: 7538520
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide nasal spray 0.03%
Study: 160741
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cyproterone acetate + 0.05 mg ethinyl estradiol (Diane)
Study: 31348806
Drug: OS-Citicoline 500
Normalized name: citicoline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS-Citicoline 500 mg/day for 6 months
Study: 31348806
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NN Group)
Study: 31348806
Drug: OS-Citicoline 500
Normalized name: citicoline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS-Citicoline 500 mg/day for 6 months followed by 3 months wash-out (NC Group)
Study: 28238601
Drug: ExPEC4V vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPEC4V vaccine
Study: 9532986
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg four times a day from 36 weeks of gestation until delivery
Study: 8032955
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 500 mg/m2 and leucovorin (LV) 500 mg/m2 intravenously weekly for 6 weeks followed by 2 weeks' rest and interferon alfa-2b 8 million units (MU) subcutaneously tiw with no rest period.
Study: 8032955
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and leucovorin (LV) with interferon alfa-2b at doses of 1, 3, 5, 8, or 10 MU.
Study: 270473
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 6-mercaptopurine (6-MP), vincristine, prednisone, and intrathecal methotrexate (MTX)
Study: 270473
Drug: Additional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional immunotherapy with BCG or allogenic myeloblasts
Study: 270473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of polychemotherapy and immunotherapy with neuraminidase-treated myeloblasts
Study: 270473
Drug: Ara-C infusion
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ara-C infusion therapy combined with 3 days of daunorubicin and inoculation with methanol extraction supernatant of tubercle bacilli
Study: 27881565
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 or 100 mg daily)
Study: 19549403
Drug: CAG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAG regimen (low-dose cytarabine and aclarubicin with G-CSF)
Study: 19549403
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anthracycline in combination with cytarabine)
Study: 15189174
Drug: Chronic renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic renal failure (CRF) patients with tHcy ≥ 25 micromol/L
Study: 7947368
Drug: celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol (200 mg daily)
Study: 7947368
Drug: nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (40 mg daily)
Study: 3030900
Drug: ispaghula husk
Normalized name: Ispaghula husk
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ispaghula husk 10 g
Study: 3030900
Drug: ispaghula husk
Normalized name: Ispaghula husk
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ispaghula husk 20 g
Study: 3030900
Drug: ispaghula husk
Normalized name: Ispaghula husk
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ispaghula husk 30 g
Study: 3030900
Drug: ispaghula husk
Normalized name: Ispaghula husk
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ispaghula husk 10 g, 20 g, 30 g (in random order)
Study: 31811498
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy, administered three times a week during RT.
Study: 28597973
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 4 g/day OM3‐CA
Study: 28597973
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day OM3‐CA
Study: 23312683
Drug: Low-flow nasal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow nasal prongs therapy with room air (1 L/min)
Study: 20698734
Drug: Daily salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily salt intake (18.01 g/day)
Study: 14597872
Drug: Paclitaxel (PAC)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PAC) 100 mg/m2 infused over 1 hour
Study: 14597872
Drug: Paclitaxel (PAC)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PAC) 100 mg/m2 infused over 3 hours